TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15303255

Group type: EXPERIMENTAL
Intervention: Ylang-ylang oil (Cananga odorata) inhalation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Odorless placebo
Number of subjects: 24
Study: 11417953

Group type: EXPERIMENTAL
Intervention: Dopexamine (1 microg/kg/min)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (without renal dysfunction)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (with renal dysfunction)
Number of subjects: 48
Study: 9813876

Group type: EXPERIMENTAL
Intervention: 20% glucose polymer (G)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 20% fructose (F)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sweet placebo (P)
Number of subjects: 8
Study: 7816382

Group type: EXPERIMENTAL
Intervention: Dipyridamole infusion
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Myocardial SPECT with 99Tcm-sestamibi
Number of subjects: 42

Group type: COMPARATOR
Intervention: Left ventricular ejection fraction (LVEF)
Number of subjects: 42
Study: 3234614

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg twice daily
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Trimoprostil 3 mg twice daily
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Trimoprostil 3 mg at bedtime
Number of subjects: 120
Study: 31821741

Group type: EXPERIMENTAL
Intervention: History of autoimmune disease
Number of subjects: 3112

Group type: EXPERIMENTAL
Intervention: History of allergy
Number of subjects: 3112

Group type: EXPERIMENTAL
Intervention: Use of immunosuppressive drugs
Number of subjects: 3112

Group type: EXPERIMENTAL
Intervention: History of inflammatory bowel disease (IBD)
Number of subjects: 3112

Group type: EXPERIMENTAL
Intervention: History of asthma
Number of subjects: 3112

Group type: EXPERIMENTAL
Intervention: Long-term duration diabetes
Number of subjects: 3112
Study: 30139624

Group type: EXPERIMENTAL
Intervention: Milk with 80:20 casein-to-whey protein ratio at 3.1% concentration
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Milk with 40:60 casein-to-whey protein ratio at 3.1% concentration
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Milk with 80:20 casein-to-whey protein ratio at 9.3% concentration
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Milk with 40:60 casein-to-whey protein ratio at 9.3% concentration
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (water with whey permeate)
Number of subjects: 32
Study: 28346730

Group type: EXPERIMENTAL
Intervention: Cheese supplemented with Lactobacillus acidophilus NCFM (T1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cheese supplemented with Lactobacillus rhamnosus Lr‐32 (T2)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control cheese (C)
Number of subjects: 60
Study: 26335087

Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA) 1,470 mg/d plus 147 mg/d of eicosapentaenoic acid (EPA)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA)
Number of subjects: 110
Study: 23061976

Group type: EXPERIMENTAL
Intervention: Q/LAIV delivered using a BFS device
Number of subjects: 1800

Group type: COMPARATOR
Intervention: T/LAIV (trivalent live attenuated influenza vaccine)
Number of subjects: 1800
Study: 21727881

Group type: COMPARATOR
Intervention: Postoperative dressings (Control group)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: No postoperative dressings (Study group)
Number of subjects: 123
Study: 18354393

Group type: EXPERIMENTAL
Intervention: Depot leuprolide acetate (Lupron) every 4 weeks for 3 months (men) or 5 months (women) + testosterone enanthate (200 mg intramuscularly) every 2 weeks for 1 month (men)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Depot leuprolide acetate (Lupron) every 4 weeks for 5 months (women) + estradiol and progesterone for 5 weeks each
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (for men during the testosterone phase)
Number of subjects: 40
Study: 17006278

Group type: EXPERIMENTAL
Intervention: Intranasal CAIV-T (live attenuated cold-adapted influenza vaccine)
Number of subjects: 2229

Group type: COMPARATOR
Intervention: Injectable TIV (trivalent inactivated influenza vaccine)
Number of subjects: 2229

Group type: EXPERIMENTAL
Intervention: Intranasal CAIV-T
Number of subjects: 2229

Group type: COMPARATOR
Intervention: Injectable TIV
Number of subjects: 2229

Group type: EXPERIMENTAL
Intervention: Intranasal CAIV-T and Injectable TIV
Number of subjects: 2229
Study: 12733421

Group type: EXPERIMENTAL
Intervention: Interrogators with guilty expectations
Number of subjects: 52

Group type: COMPARATOR
Intervention: Interrogators with innocent expectations
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Neutral observers listening to audiotapes
Number of subjects: 52
Study: 10694188

Group type: EXPERIMENTAL
Intervention: Lacidipine
Number of subjects: 2259

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 2259
Study: 9201603

Group type: EXPERIMENTAL
Intervention: Glutathione i.v. administration (1 g/m2 bolus + 1 g/m2 in 2 h)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test + glutathione administration
Number of subjects: 20

Group type: COMPARATOR
Intervention: Oral glucose tolerance test
Number of subjects: 20
Study: 8450082

Group type: EXPERIMENTAL
Intervention: Mechanical interdental cleaning plus toothbrushing
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Antimicrobial mouthrinse (0.12% chlorhexidine gluconate) plus toothbrushing
Number of subjects: 92

Group type: COMPARATOR
Intervention: Toothbrushing alone
Number of subjects: 92
Study: 3426836

Group type: EXPERIMENTAL
Intervention: L-phenylalanine (high phe)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: L-alanine (low phe)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Unrestricted diet
Number of subjects: 9
Study: 30002145

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (20 mg once daily, or 15 mg based on kidney function)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Warfarin (international normalized ratio target 2.5)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Rivaroxaban vs Warfarin
Number of subjects: 120
Study: 27820761

Group type: EXPERIMENTAL
Intervention: Phone coaching
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Small group coaching
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-study
Number of subjects: 0
Study: 25411740

Group type: EXPERIMENTAL
Intervention: rhPDGF + β-TCP
Number of subjects: 15

Group type: COMPARATOR
Intervention: β-TCP alone
Number of subjects: 15
Study: 22672058

Group type: COMPARATOR
Intervention: Inulin 10 g
Number of subjects: 20

Group type: COMPARATOR
Intervention: Inulin 20 g
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: SGF 40 g (acute consumption)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: SGF 65 g (spread over the day)
Number of subjects: 20
Study: 20690168

Group type: EXPERIMENTAL
Intervention: Trauma Risk Management (TRiM)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 12
Study: 17927795

Group type: EXPERIMENTAL
Intervention: ReCell treatment
Number of subjects: 5

Group type: COMPARATOR
Intervention: Conventional melanocyte-keratinocyte transplantation (MKT)
Number of subjects: 5
Study: 17186712

Group type: EXPERIMENTAL
Intervention: Trospium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Solifenacin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Darifenacin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oxybutynin (immediate-release)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tolterodine (immediate-release)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Extended-release formulations of Tolterodine or Oxybutynin
Number of subjects: 0
Study: 12762623

Group type: EXPERIMENTAL
Intervention: Aerobic training (A)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Aerobic and strength training (AS)
Number of subjects: 52
Study: 11164433

Group type: EXPERIMENTAL
Intervention: Leisure time physical activity
Number of subjects: 1778

Group type: COMPARATOR
Intervention: TV watching
Number of subjects: 1778

Group type: EXPERIMENTAL
Intervention: Leisure time physical activity and TV watching
Number of subjects: 1778
Study: 9264626

Group type: EXPERIMENTAL
Intervention: Brief medical counselling backed up by didactic material
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 152
Study: 8383657

Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam
Number of subjects: 113

Group type: COMPARATOR
Intervention: Imipenem/cilastatin
Number of subjects: 113
Study: 3082257

Group type: EXPERIMENTAL
Intervention: Cromolyn sodium (CS) pressurized aerosol, 1 mg per puff, 2 puffs, four times daily for 4 weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo, 2 puffs, four times daily for 4 weeks
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Cromolyn sodium (CS) pressurized aerosol
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 31809457

Group type: EXPERIMENTAL
Intervention: Muscle Failure (MF) training protocol
Number of subjects: 10

Group type: COMPARATOR
Intervention: No Muscle Failure (NMF) training protocol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both MF and NMF protocols
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: NMF training
Number of subjects: 10
Study: 31520633

Group type: EXPERIMENTAL
Intervention: Adjuvant Radiation Therapy (RT)
Number of subjects: 1215

Group type: COMPARATOR
Intervention: No Adjuvant Radiation Therapy (RT)
Number of subjects: 1215
Study: 27449925

Group type: EXPERIMENTAL
Intervention: Vitamin D3-enriched Gouda-type cheese (60 g providing 5.7 μg of vitamin D3 daily)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Non-enriched Gouda-type cheese (control group)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Vitamin D3-enriched Gouda-type cheese
Number of subjects: 79
Study: 26860022

Group type: EXPERIMENTAL
Intervention: I-GEL
Number of subjects: 64

Group type: COMPARATOR
Intervention: Endotracheal Tube (ETT)
Number of subjects: 64
Study: 23167912

Group type: EXPERIMENTAL
Intervention: M‐MIST with rhPDGF‐BB gel
Number of subjects: 24

Group type: COMPARATOR
Intervention: M‐MIST alone
Number of subjects: 24
Study: 21296957

Group type: EXPERIMENTAL
Intervention: Fish oil (5.0 g daily, containing 2.0 g of EPA and 1.0 g of DHA)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo oil (5.0 g of corn/soy mixture)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 116
Study: 19467834

Group type: COMPARATOR
Intervention: Isothermic cardioplegia alone
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Cardioplegia enriched with NAC (50mg/kg body weight)
Number of subjects: 53
Study: 17088135

Group type: EXPERIMENTAL
Intervention: Children with mild asthma
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Children with moderate-severe asthma
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Children with asthma with GSTP1 val/val genotype
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: GSTP1 val/val genotype
Number of subjects: 196

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 196
Study: 15248793

Group type: EXPERIMENTAL
Intervention: Normal speech intervention (12 children)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Manipulated speech intervention (12 children)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (12 children)
Number of subjects: 24
Study: 11374698

Group type: EXPERIMENTAL
Intervention: N2O/O2 inhalation (50% N2O/O2)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (breathing oxygen)
Number of subjects: 100
Study: 9258161

Group type: EXPERIMENTAL
Intervention: Penile block after surgery
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Penile block before surgery
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Penile block before and after surgery
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (after surgery only)
Number of subjects: 98
Study: 8299548

Group type: EXPERIMENTAL
Intervention: Antidepressant medication (specific type not mentioned)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monoamine oxidase inhibitor (MAOI) phenelzine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tricyclic therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlorpromazine and lithium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anti-depressants
Number of subjects: 0
Study: 2936958

Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 1

Group type: COMPARATOR
Intervention: Placebo or alternative treatment
Number of subjects: 1
Study: 31036033

Group type: EXPERIMENTAL
Intervention: 3D adjustable cervico thoracic posture corrective orthotic (CTPCO)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional treatment (moist hot pack, soft tissue mobilization, manual therapy, therapeutic exercise)
Number of subjects: 24
Study: 27760505

Group type: EXPERIMENTAL
Intervention: Upper extremity function training (UE group) for three months
Number of subjects: 15

Group type: COMPARATOR
Intervention: Lower extremity function training (LE group) for three months
Number of subjects: 15
Study: 25926725

Group type: EXPERIMENTAL
Intervention: 10 g leucine/day plus resistance training (leucine group [LG], n=15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Resistance training only (control group [CG], n=15)
Number of subjects: 30
Study: 23449843

Group type: EXPERIMENTAL
Intervention: Manipulated increase in relative right frontal cortical activity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Manipulated increase in relative left frontal cortical activity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study: 21454006

Group type: EXPERIMENTAL
Intervention: AED with audiovisual feedback enabled
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (AED with audiovisual feedback disabled)
Number of subjects: 68
Study: 19631788

Group type: EXPERIMENTAL
Intervention: Frameless IUD (GyneFix)
Number of subjects: 4063

Group type: COMPARATOR
Intervention: TCu380A IUD
Number of subjects: 4063
Study: 16368340

Group type: EXPERIMENTAL
Intervention: Preoperative statin therapy
Number of subjects: 141

Group type: COMPARATOR
Intervention: Non-statin therapy
Number of subjects: 141
Study: 12600870

Group type: EXPERIMENTAL
Intervention: Glutamine supplementation (20% of total amino acids as glutamine)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Standard intravenous amino acid solution (without glutamine)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Glutamine supplementation
Number of subjects: 141
Study: 11022928

Group type: EXPERIMENTAL
Intervention: Family support
Number of subjects: 590

Group type: COMPARATOR
Intervention: Normal care
Number of subjects: 590
Study: 8852863

Group type: EXPERIMENTAL
Intervention: 2500 lux of bright light
Number of subjects: 18

Group type: COMPARATOR
Intervention: < 500 lux of dim light (placebo)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Withdrawal of light exposure
Number of subjects: 18
Study: 1537959

Group type: EXPERIMENTAL
Intervention: Methylphenidate (35.21 mg/day)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 6726596

Group type: EXPERIMENTAL
Intervention: Oral iron supplements from the 16th week of amenorrhea until 6 weeks post partum
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group without iron supplementation
Number of subjects: 44
Study: 29659116

Group type: EXPERIMENTAL
Intervention: DC0120 (5% minoxidil formulation), applied twice per day for 16 weeks
Number of subjects: 220

Group type: COMPARATOR
Intervention: Comparator (ALOSTIL® minoxidil product), applied twice per day for 16 weeks
Number of subjects: 220

Group type: COMPARATOR
Intervention: DC0120 and Comparator (both minoxidil treatments)
Number of subjects: 220

Group type: COMPARATOR
Intervention: DC0120 vs Comparator
Number of subjects: 220
Study: 28935431

Group type: EXPERIMENTAL
Intervention: Anterolateral portal for suture anchor placement
Number of subjects: 10

Group type: COMPARATOR
Intervention: Posterolateral portal for suture anchor placement
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Biomechanical strength assessment
Number of subjects: 10
Study: 27572136

Group type: EXPERIMENTAL
Intervention: Intravenous methadone (0.1-0.125 mg/kg) in addition to standard care
Number of subjects: 47

Group type: COMPARATOR
Intervention: Standard care (opioid patient-controlled analgesia)
Number of subjects: 47
Study: 24699248

Group type: EXPERIMENTAL
Intervention: GSK263 (300 mg BID)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: GSK263 (co-dosed with metformin)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Sitagliptin (100 mg/day)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Sitagliptin (co-dosed with metformin)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: GSK263
Number of subjects: 141
Study: 21337116

Group type: EXPERIMENTAL
Intervention: CPAP treatment for 1 month
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard care alone (Control)
Number of subjects: 24
Study: 20036477

Group type: EXPERIMENTAL
Intervention: Faropenem
Number of subjects: 0
Study: 18614738

Group type: EXPERIMENTAL
Intervention: Fish oil (4 capsules of 1g providing 2.7g n-3 PUFAs per day)
Number of subjects: 533

Group type: COMPARATOR
Intervention: Olive oil (4 capsules of 1g per day)
Number of subjects: 533

Group type: COMPARATOR
Intervention: No oil capsules
Number of subjects: 533
Study: 16139934

Group type: EXPERIMENTAL
Intervention: 27-gauge (dental) needle
Number of subjects: 86

Group type: COMPARATOR
Intervention: 23-gauge needle
Number of subjects: 86
Study: 11854696

Group type: EXPERIMENTAL
Intervention: 20 units of botulinum toxin (retreatment with 30 units if fissure persisted)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 30 units of botulinum toxin (retreatment with 50 units if fissure persisted)
Number of subjects: 150
Study: 10235530

Group type: EXPERIMENTAL
Intervention: IGF-1/IGFBP-3 treatment at 1.0 mg/kg/day
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: IGF-1/IGFBP-3 treatment at 2.0 mg/kg/day
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: IGF-1/IGFBP-3 treatment at 4.0 mg/kg/day
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (no IGF-1/IGFBP-3 treatment)
Number of subjects: 29
Study: 8904257

Group type: EXPERIMENTAL
Intervention: Vecuronium 0.056 mg/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Vecuronium 0.14 mg/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Vecuronium 0.28 mg/kg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Atracurium 0.28 mg/kg
Number of subjects: 40
Study: 1824542

Group type: EXPERIMENTAL
Intervention: Casein formula (1.4 gm protein/100 ml)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supplemented human milk (1.4 gm protein/100 ml)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (fresh human milk)
Number of subjects: 0
Study: 6405766

Group type: EXPERIMENTAL
Intervention: Morphine hydrochloride 0.4 mg with isobaric 0.5% bupivacaine
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Morphine 0.2 mg (older patients only)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2
Study: 30665731

Group type: EXPERIMENTAL
Intervention: DVD (n = 217)
Number of subjects: 442

Group type: COMPARATOR
Intervention: In-person, group class (n = 225)
Number of subjects: 442
Study: 29106676

Group type: EXPERIMENTAL
Intervention: Taurolock/Hep
Number of subjects: 164

Group type: COMPARATOR
Intervention: Taurolock/U
Number of subjects: 164
Study: 26297132

Group type: EXPERIMENTAL
Intervention: Ingested 0.3 g of raw salmon
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ingested 30 g of raw salmon
Number of subjects: 10
Study: 23972906

Group type: EXPERIMENTAL
Intervention: Nurse led care coordination with experienced nurse practitioners and a best practice resource guide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study: 22595107

Group type: EXPERIMENTAL
Intervention: 1.8 mL of 2% lidocaine with 1:200,000 epinephrine
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 3.6 mL of 2% lidocaine with 1:200,000 epinephrine
Number of subjects: 55
Study: 19467149

Group type: EXPERIMENTAL
Intervention: Multicomponent physical activity counseling (PAC)
Number of subjects: 398

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 398
Study: 17460331

Group type: EXPERIMENTAL
Intervention: 3 mg/kg caffeine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 6 mg/kg caffeine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 15509514

Group type: EXPERIMENTAL
Intervention: AdvHSV‐tk gene therapy (3 x 10(10) pfu) followed by intravenous ganciclovir (GCV), 5 mg/kg twice daily for 14 days
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard care (radical excision followed by radiotherapy)
Number of subjects: 36
Study: 10702179

Group type: EXPERIMENTAL
Intervention: Preterm formula
Number of subjects: 926

Group type: COMPARATOR
Intervention: Banked donor breast milk
Number of subjects: 926

Group type: COMPARATOR
Intervention: Standard term formula
Number of subjects: 926
Study: 9322826

Group type: EXPERIMENTAL
Intervention: nifedipine-capsules (10 mg)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: captopril (25 mg)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: nifedipine-retard (20 mg)
Number of subjects: 46
Study: 8447800

Group type: EXPERIMENTAL
Intervention: Phenytoin treatment
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 3462391

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 30

Group type: COMPARATOR
Intervention: Comparison of Lidocaine and Saline
Number of subjects: 30
Study: 2967783

Group type: EXPERIMENTAL
Intervention: Gestodene
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Desogestrel
Number of subjects: 20

Group type: COMPARATOR
Intervention: Both antiovulants
Number of subjects: 20
Study: 31770598

Group type: EXPERIMENTAL
Intervention: Antimicrobial photodynamic therapy (APDT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP)
Number of subjects: 0
Study: 31229609

Group type: EXPERIMENTAL
Intervention: Flipped classroom (home pre‐taped lectures followed by in‐class group exercise)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional classroom (home reading assignment followed by in‐class lecture)
Number of subjects: 40